I don’t expect NVS and MNTA to have any interest in developing a Copaxone product in markets such as India and Ukraine. That Natco is already doing it makes it even less attractive from a business standpoint.
MNTA’s interest in generic Copaxone will likely be limited to the US, which accounts for about 70% of worldwide Copaxone sales. Most of the remaining 30% comes from the EU, but only a few EU countries allow US-style automatic substitution of a generic for a branded drug. In short, the business proposition for developing generic Copaxone in non-US markets is tenuous at best.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.